Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04798781 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
A Phase 2 study, sponsored by Andrew Hendifar, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04798781 is a Phase 2 study that has completed, run by Andrew Hendifar, MD. The registered enrollment target is 16 participants.
The verdict
NCT04798781, a Phase 2 study, has completed, sponsored by Andrew Hendifar, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.
Interventions
- DRUG Keytruda
- DRUG Telatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2025-10-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04798781
The ClinicalTrials.gov registry entry for NCT04798781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Hendifar, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Keytruda is the first listed.
NCT04798781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04798781 about?
NCT04798781 is a clinical study titled "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma". This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.
What is the current status of trial NCT04798781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-07-28. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT04798781?
The interventions under investigation include: Keytruda (DRUG), Telatinib (DRUG).
Who is sponsoring clinical trial NCT04798781?
This trial is sponsored by Andrew Hendifar, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.